As millions take these medications for long periods of time, unexpected GLP-1 side effects are starting to emerge
This condition is known as peripheral artery disease (PAD)
Unapproved device concerns FDA raised concerns about Zoll's RescueNet Live software, stating that if the software analyzes data from a monitoring device and generates a secondary alarm and is not merely receiving and displaying alarms, then it is a medical device and is adulterated because Zoll "does not have an approved application for premarket approval (PMA) in effect." Company responses Zoll submitted multiple responses between May 2025 and April 2026 from various quality assurance personnel
These leaked electrons are responsible for the release of superoxide radical in the mitochondria (Benzi et al., 1992
Companies like Pfizer, AstraZeneca, Sanofi, and Roche are investing in next-gen GLP-1s, dual and triple agonists, and even oral formulations to compete in whats now a multi-billion-dollar therapeutic category
Clinical studies have shown that low levels of IGF-1 are associated with an increased risk of cardiovascular diseases, including coronary heart disease and stroke